Prescient Therapeutics Ltd T Small Caps to Discuss the Company's Innovative Pipeline of Personalised Cancer Therapies Transcript
Welcome back to Small Caps. My name is Kerry Stevenson. Today, we're bringing you Prescient Therapeutics. They are a clinical-stage company developing personalized therapies. Joining me today is the MD and CEO, Steven Yatomi-Clarke.
Steven, thank you for joining me today. There is some fantastic news that you guys have put out to the market. I'm excited to tell our audience about what you're doing. You're an ASX-listed company. And for those of you that don't know, the ASX code is PTX. Write that down, ladies and gentlemen, because what we're talking about now is these guys are making some big head roads into these clinical-stage trials they are doing, et cetera.
So Steven, before we get started, just explain to everyone out there who are Prescient Therapeutics, just a bit of an overview.
Prescient Therapeutics, we focus on oncology. If I was to be able to capture the many things that we're doing, is personalizing cancer
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
